Korro Bio, Inc., a biopharmaceutical company specializing in RNA therapy development, recently disclosed details regarding the sale of common stock by its President and CEO, Aiyar Ram. The transaction involved the disposition of shares that had vested under the company’s 2023 Stock-Option and Incentive Plan. A portion of the proceeds from this sale was allocated to satisfy a tax obligation arising from the vesting of these shares.
The company’s filings also revealed that Aiyar Ram had sold additional shares in the preceding three months, indicating active participation in Korro Bio’s equity program. These transactions highlight the ongoing share-vesting activities and the related liquidity movements within the company.
Korro Bio, Inc. is listed on the Nasdaq and operates in the Health Care sector. The company is headquartered in Cambridge, Massachusetts, and serves its U.S. clientele through its operations there. Korro Bio’s mission is to develop and distribute RNA therapies informed by human genetics and disease biology, aiming to address both rare and highly common diseases.
As of August 4, 2026, the close price of Korro Bio’s stock was $11.5. The company’s market capitalization stands at approximately $163.7 million USD. Over the past year, the stock has experienced significant volatility, with a 52-week high of $55.89 on October 15, 2025, and a 52-week low of $5.204 on December 1, 2025. The price-to-earnings ratio is currently -0.9, reflecting the company’s financial performance and market valuation.
No new business developments or operational updates were included in the recent filings. Korro Bio continues to focus on its core mission of developing RNA therapies, leveraging its expertise in human genetics and disease biology to address a wide range of medical conditions. For more information, stakeholders can visit the company’s website at www.korrobio.com .
